AR085726A1 - Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento - Google Patents

Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento

Info

Publication number
AR085726A1
AR085726A1 ARP120101045A ARP120101045A AR085726A1 AR 085726 A1 AR085726 A1 AR 085726A1 AR P120101045 A ARP120101045 A AR P120101045A AR P120101045 A ARP120101045 A AR P120101045A AR 085726 A1 AR085726 A1 AR 085726A1
Authority
AR
Argentina
Prior art keywords
mip
eotaxin
mcp
immunoglobulin
heavy chain
Prior art date
Application number
ARP120101045A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46927552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR085726A1 publication Critical patent/AR085726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

También se proporcionan métodos para elaborar tales proteínas de unión de tipo antígeno. Reivindicación 1: Una proteína de unión de tipo anticuerpo que comprende cuatro cadenas polipeptídicas que forman cuatro sitios de unión al antígeno, donde dos cadenas polipeptídicas tienen una estructura representada por la fórmula: VL₁-L₁-VL₂-L₂-CL [1] y dos cadenas polipeptídicas tienen una estructura representada por la fórmula: VH₂-L₃-VH₁-L₄-CH₁-FC [2] donde: VL₁ es un primer dominio variable de la cadena ligera de la inmunoglobulina; VL₂ es un segundo dominio variable de la cadena ligera de la inmunoglobulina; VH₁ es un primer dominio variable de la cadena pesada de la inmunoglobulina; VH₂ es un segundo dominio variable de la cadena pesada de la inmunoglobulina; CL es un dominio constante de la cadena ligera de la inmunoglobulina; CH₁ es un dominio constante de la cadena pesada CH₁ de la inmunoglobulina; FC es la región bisagra de la inmunoglobulina y CH₂, CH₃ los dominios constantes de la cadena pesada de la inmunoglobulina; y L₁, L₂, L₃, y L₄ son conectores aminoacídicos; y donde los polipéptidos de fórmula [1] y los polipéptidos de fórmula [2] forman un par de cadena ligera-cadena pesada entrecruzadas. Reivindicación 7: La proteína de unión de tipo anticuerpo de la reivindicación 6, donde las una o más dianas antigénicas se seleccionan del grupo que consiste en B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxina), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxina 2), CCL25 (TECK), CCL26 (eotaxina 3), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (cadherina E), Quitinasa, CSF1 (MCSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, FCER1A, FCER2, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL2, IL4, IL22, IL23, IL25, IL27, IL7, IL8, IL9, ITGB4 (integrina b4), LEP (leptina), TLR2, TLR4, TLR5, TNF, TNF-a, TNFSF4 (ligando OX40), TNFSF5 (ligando CD40), receptores de tipo TolI, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1 (CLEC91), y HMGB1. Reivindicación 31: La proteína de unión de tipo anticuerpo de la reivindicación 2, donde las una o más dianas antigénicas se seleccionan del grupo que consiste en B7.1, B7.2, BAFF, BlyS, C3, C5, CCL11 (eotaxina), CCL15 (MIP-1d), CCL17 (TARC), CCL19 (MIP-3b), CCL2 (MCP-1), CCL20 (MIP-3a), CCL21 (MIP-2), SLC, CCL24 (MPIF-2/eotaxina 2), CCL25 (TECK), CCL26 (eotaxina 3), CCL3 (MIP-1a), CCL4 (MIP-1b), CCL5 (RANTES), CCL7 (MCP-3), CCL8 (mcp-2), CD3, CD19, CD20, CD24, CD40, CD40L, CD80, CD86, CDH1 (cadherina E), Quitinasa, CSF1 (MCSF), CSF2 (GM-CSF), CSF3 (GCSF), CTLA4, CX3CL1 (SCYD1), CXCL12 (SDF1), CXCL13, FCER1A, FCER2, IL-1, IL-12, IL13, IL15, IL17, IL18, IL1A, IL1B, IL1F10, IL2, IL4, IL22, IL23, IL25, IL27, IL7, IL8, IL9, ITGB4 (integrina b4), LEP (leptina), TLR2, TLR4, TLR5, TNF, TNF-a, TNFSF4 (ligando OX40), TNFSF5 (ligando CD40), receptores de tipo TolI, TREM1, TSLP, TWEAK, XCR1 (GPR5/CCXCR1), DNGR-1 (CLEC91), y HMGB1.
ARP120101045A 2011-03-28 2012-03-28 Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento AR085726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161468276P 2011-03-28 2011-03-28
FR1160311 2011-11-14

Publications (1)

Publication Number Publication Date
AR085726A1 true AR085726A1 (es) 2013-10-23

Family

ID=46927552

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP120101045A AR085726A1 (es) 2011-03-28 2012-03-28 Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento
ARP210103666A AR124511A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103668A AR124513A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103667A AR124512A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento

Family Applications After (3)

Application Number Title Priority Date Filing Date
ARP210103666A AR124511A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103668A AR124513A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento
ARP210103667A AR124512A2 (es) 2011-03-28 2021-12-23 Proteínas de unión de tipo anticuerpo con región variable dual que tienen orientación de la región de unión con entrecruzamiento

Country Status (31)

Country Link
US (7) US20120251541A1 (es)
EP (4) EP3112380A1 (es)
JP (6) JP6023172B2 (es)
KR (3) KR102607708B1 (es)
CN (3) CN110256568A (es)
AR (4) AR085726A1 (es)
AU (1) AU2012236603B2 (es)
BR (3) BR112013024758B1 (es)
CA (1) CA2831603C (es)
CL (1) CL2018001827A1 (es)
CO (1) CO6781527A2 (es)
CY (1) CY1118807T1 (es)
DK (2) DK3199547T3 (es)
ES (1) ES2588306T3 (es)
HR (1) HRP20161030T1 (es)
HU (1) HUE028230T2 (es)
IL (4) IL299392A (es)
LT (1) LT2691416T (es)
MA (1) MA35051B1 (es)
MX (1) MX338907B (es)
MY (1) MY164906A (es)
PL (2) PL2691416T3 (es)
PT (1) PT2691416T (es)
RS (2) RS55014B1 (es)
RU (1) RU2695880C2 (es)
SG (1) SG193916A1 (es)
SI (2) SI2691416T1 (es)
TW (6) TWI671315B (es)
UY (1) UY33983A (es)
WO (1) WO2012135345A1 (es)
ZA (1) ZA201307017B (es)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
TWI671315B (zh) * 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HUE049860T2 (hu) 2012-02-13 2020-11-30 Agency Science Tech & Res IL-ß-t neutralizáló, humán monoklonális antitestek
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
MX366103B (es) 2012-09-12 2019-06-27 Genzyme Corp Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida.
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014106004A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CN110981964B (zh) 2013-01-14 2023-09-15 Xencor股份有限公司 新型异二聚体蛋白
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9844607B2 (en) * 2013-02-05 2017-12-19 Sanofi Immuno imaging agent for use with antibody-drug conjugate therapy
KR20240023184A (ko) 2013-03-11 2024-02-20 젠자임 코포레이션 과글리코실화된 결합 폴리펩티드
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CA2903258C (en) * 2013-03-15 2019-11-26 Amgen Inc. Heterodimeric bispecific antibodies
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
CN103509117B (zh) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 抗人her2和人igf-ir的双特异性抗体及其制备方法和用途
DK3024851T3 (en) 2013-07-25 2018-08-06 Cytomx Therapeutics Inc MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
CN104418947A (zh) * 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3102681B1 (en) * 2014-02-07 2023-10-04 McMaster University Trifunctional t cell-antigen coupler and methods and uses thereof
FI3129067T3 (fi) 2014-03-19 2023-04-04 Genzyme Corp Kohdennusosien kohtaspesifinen glykomodifiointi
WO2015149077A1 (en) 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
CN104974258B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗hgf/dll4双特异性抗体、其制备方法和应用
US10647777B2 (en) 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
TW201628647A (zh) * 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
AU2015289124B2 (en) * 2014-07-18 2021-03-11 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP6746564B2 (ja) * 2014-09-03 2020-08-26 ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用
AU2015330869B2 (en) 2014-10-09 2021-07-08 Genzyme Corporation Glycoengineered antibody drug conjugates
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CU24597B1 (es) 2014-11-26 2022-05-11 Xencor Inc Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20
KR20170084327A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Cd3 및 cd38에 결합하는 이형이량체 항체
WO2016094834A2 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
CA2966776C (en) * 2014-12-19 2021-05-04 Alkermes, Inc. Single chain fc fusion proteins
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
CN113105553B (zh) 2014-12-22 2024-09-10 成都百利多特生物药业有限责任公司 双特异性四价抗体及其制造和使用方法
CN107428835B (zh) 2015-01-23 2021-11-26 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016154290A1 (en) 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
US11571462B2 (en) 2015-06-03 2023-02-07 The Medical College Of Wisconsin, Inc. Engineered CCL20 locked dimer polypeptide
ES2776243T3 (es) 2015-06-03 2020-07-29 Medical College Wisconsin Inc Un polipéptido de dímero CCL20 bloqueado modificado por ingeniería
EA201890041A1 (ru) * 2015-06-15 2018-07-31 Нумаб Инновейшн Аг Гетеродимерный полиспецифичный формат антител
JP6866345B2 (ja) * 2015-07-23 2021-04-28 ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー Ｉｌ−２３ａ及びｂ細胞活性化因子（ｂａｆｆ）を標的とする化合物及びその使用
JP2018528218A (ja) 2015-09-11 2018-09-27 アンドリアン、ブルース 組換えグリコシル化エクリズマブおよびエクリズマブ変異体
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
WO2017059900A1 (en) * 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3156417A1 (en) 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
CN116789841A (zh) * 2015-10-25 2023-09-22 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
CN109400709B (zh) * 2015-11-13 2021-03-23 广东医科大学 双功能抗体及其用途
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
KR20240036142A (ko) 2016-04-13 2024-03-19 사노피 3특이성 및/또는 3가 결합 단백질
AU2017248671B2 (en) * 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING REFRACTORY GENERALIZED MYASTHENIA GRAVIS
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US10335459B2 (en) 2016-06-22 2019-07-02 Alkermes, Inc. Compositions for modulating IL-10 immunostimulatory and anti-inflammatory properties
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
AU2017315146A1 (en) 2016-08-26 2019-04-11 Sanofi Multispecific antibodies facilitating selective light chain pairing
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
BR112019007281A2 (pt) 2016-10-14 2019-07-09 Xencor Inc proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
WO2018075761A1 (en) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
WO2018075758A1 (en) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
EP3615566B1 (en) * 2017-04-28 2023-12-20 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
MX2019013370A (es) * 2017-05-10 2020-08-03 Wistar Inst Constructos de anticuerpos de ácidos nucleicos optimizados.
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
WO2019074973A2 (en) 2017-10-10 2019-04-18 Sanofi ANTI-CD38 ANTIBODIES AND METHODS OF USE
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University T-CELL ANTIGEN COUPLER WITH Y182T MUTATION, AND PROCEDURES AND USES THEREOF
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3728302A1 (en) 2017-12-19 2020-10-28 Xencor, Inc. Engineered il-2 fc fusion proteins
UY38050A (es) * 2018-01-12 2019-07-31 Amgen Inc Anticuerpos pac1 y sus usos referencia cruzada a solicitudes relacionadas
US11067584B2 (en) 2018-01-12 2021-07-20 Genzyme Corporation Methods for the quantitation of polypeptides
TW201940512A (zh) 2018-01-26 2019-10-16 美商健臻公司 具有與ＦｃＲｎ增進的結合及延長的半衰期之Ｆｃ變異體
EP3768705A1 (en) * 2018-03-22 2021-01-27 Universität Stuttgart Multivalent binding molecules
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
US10640562B2 (en) 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US20220002393A1 (en) 2018-11-20 2022-01-06 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis in pediatric patients
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
JP2022515424A (ja) 2018-12-24 2022-02-18 サノフイ 突然変異ｆａｂドメインを有する多重特異性結合タンパク質
BR112021012337A2 (pt) 2018-12-24 2021-09-14 Sanofi Proteínas de ligação multiespecíficas baseadas em pseudofab
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3136821A1 (en) * 2019-04-09 2020-10-15 Sanofi Trispecific binding proteins, methods, and uses thereof
MA56120A (fr) * 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
EP4004039A2 (en) 2019-07-25 2022-06-01 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021026160A1 (en) 2019-08-05 2021-02-11 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis with eculizumab
KR20220062494A (ko) * 2019-08-15 2022-05-17 얀센 바이오테크 인코포레이티드 개선된 단일 사슬 가변 단편을 위한 재료 및 방법
IL292480A (en) 2019-10-25 2022-06-01 Sanofi Sa Methods for the analysis of chain mispairs in multispecific binding proteins
KR20220106793A (ko) 2019-11-25 2022-07-29 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US11879004B2 (en) 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
IL296428A (en) 2020-03-25 2022-11-01 Lilly Co Eli Multispecific binding proteins and methods for their development
CN115380048A (zh) * 2020-03-30 2022-11-22 赛诺菲 分裂ch2结构域
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
CA3192465A1 (en) 2020-09-18 2022-03-24 Laure Bouchez Cd47-cd38 bispecific antibodies
EP4277931A1 (en) 2021-01-13 2023-11-22 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
MX2023012902A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a prame.
BR112023022584A2 (pt) 2021-05-27 2024-01-09 Sanofi Sa Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada
WO2022256449A1 (en) 2021-06-01 2022-12-08 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
TW202330598A (zh) * 2021-06-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂａｆｆ和ｉｌ－１２／２３的抗原結合分子及用途
IL311765A (en) * 2021-09-29 2024-05-01 Modex Therapeutics Inc Antigen-binding polypeptides, antigen-binding polypeptide complexes and methods of using them
JP2024540728A (ja) 2021-11-02 2024-11-01 ビステラ， インコーポレイテッド ＦＣＧａｍｍａｒおよびＣ１Ｑへの結合が無効化されたＦＣバリアント
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
MX2024010771A (es) * 2022-03-03 2024-09-10 Pfizer Inc Anticuerpos multiespecificos y usos de estos.
US20240228650A9 (en) 2022-05-06 2024-07-11 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
WO2023222665A1 (en) 2022-05-18 2023-11-23 Sanofi Method, system and apparatus for predicting pk values of antibodies
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
US20240018201A1 (en) 2022-06-08 2024-01-18 Sanofi Methods for purification of multi-specific antibodies
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
WO2024121311A1 (en) 2022-12-07 2024-06-13 Ichnos Sciences SA Cd47/cd38 bispecific antibodies and methods of use to treat leukemia
WO2024126833A1 (en) 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
WO2024189048A1 (en) 2023-03-13 2024-09-19 Heidelberg Pharma Research Gmbh Subcutaneously administered antibody-drug conjugates for use in cancer treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
CN1173878A (zh) * 1995-10-16 1998-02-18 尤尼利弗公司 双功能或双价抗体片段类似物
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
PT929578E (pt) 1996-02-09 2003-09-30 Abbott Lab Bermuda Ltd Anticorpos humanos que se ligam a tnfalfa humano
AU2507397A (en) 1996-04-04 1997-10-29 Unilever Plc Multivalent and multispecific antigen-binding protein
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CA2403425C (en) * 2000-04-11 2013-08-27 Genentech, Inc. Multivalent antibodies and uses therefor
PL364623A1 (en) * 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101599735B1 (ko) * 2007-06-21 2016-03-07 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
EP2178914A2 (en) * 2007-08-15 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Monospecific and multispecific antibodies and method of use
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090162359A1 (en) * 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2786762B1 (en) * 2008-12-19 2019-01-30 MacroGenics, Inc. Covalent diabodies and uses thereof
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
US9493578B2 (en) * 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20130344074A1 (en) * 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
CN107428835B (zh) * 2015-01-23 2021-11-26 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
AU2017248671B2 (en) * 2016-04-13 2024-06-20 Sanofi Trispecific and/or trivalent binding proteins
WO2019074973A2 (en) * 2017-10-10 2019-04-18 Sanofi ANTI-CD38 ANTIBODIES AND METHODS OF USE
MX2021004147A (es) * 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
US20140056895A1 (en) 2014-02-27
LT2691416T (lt) 2016-09-12
IL261674A (en) 2018-10-31
CN103562221B (zh) 2019-06-14
IL228512A0 (en) 2013-12-31
JP2017038607A (ja) 2017-02-23
AR124513A2 (es) 2023-04-05
TWI803876B (zh) 2023-06-01
HUE028230T2 (en) 2016-12-28
BR112013024758A2 (pt) 2018-07-10
WO2012135345A1 (en) 2012-10-04
JP2018087211A (ja) 2018-06-07
PL3199547T3 (pl) 2021-06-14
AR124511A2 (es) 2023-04-05
US20180155450A1 (en) 2018-06-07
KR20230166147A (ko) 2023-12-06
EP2691416B1 (en) 2016-05-18
IL228512B (en) 2018-10-31
PT2691416T (pt) 2016-08-26
TW202317615A (zh) 2023-05-01
TWI588156B (zh) 2017-06-21
IL299392A (en) 2023-02-01
EP3199547B1 (en) 2020-11-18
AR124512A2 (es) 2023-04-05
PL2691416T3 (pl) 2016-11-30
JP2014511684A (ja) 2014-05-19
CA2831603C (en) 2020-07-21
TW201302786A (zh) 2013-01-16
SI2691416T1 (sl) 2016-10-28
US9181349B2 (en) 2015-11-10
CA2831603A1 (en) 2012-10-04
BR112013024758B1 (pt) 2022-06-14
TWI622597B (zh) 2018-05-01
IL261674B (en) 2020-06-30
JP6877371B2 (ja) 2021-05-26
CN103562221A (zh) 2014-02-05
TW201722988A (zh) 2017-07-01
JP2023100752A (ja) 2023-07-19
JP6490038B2 (ja) 2019-03-27
US20130345404A1 (en) 2013-12-26
NZ616174A (en) 2015-10-30
MX2013011176A (es) 2013-11-01
IL261673A (en) 2018-10-31
AU2012236603A1 (en) 2013-04-18
KR101974901B1 (ko) 2019-05-08
US20140011238A1 (en) 2014-01-09
US20160200811A1 (en) 2016-07-14
CN110256568A (zh) 2019-09-20
JP7003101B2 (ja) 2022-02-04
EP2691416A1 (en) 2014-02-05
MA35051B1 (fr) 2014-04-03
CO6781527A2 (es) 2013-10-31
IL261673B (en) 2020-06-30
JP2022046668A (ja) 2022-03-23
KR20210042183A (ko) 2021-04-16
RU2695880C2 (ru) 2019-07-29
MX338907B (es) 2016-05-05
BR122022004041B1 (pt) 2022-12-06
HRP20161030T1 (hr) 2016-10-21
EP3112380A1 (en) 2017-01-04
JP7273135B2 (ja) 2023-05-12
RU2013147821A (ru) 2015-05-20
TWI671315B (zh) 2019-09-11
KR20140019420A (ko) 2014-02-14
EP3805262A1 (en) 2021-04-14
US20120251541A1 (en) 2012-10-04
SG193916A1 (en) 2013-11-29
JP6023172B2 (ja) 2016-11-09
US20210189011A1 (en) 2021-06-24
CY1118807T1 (el) 2018-01-10
TWI743461B (zh) 2021-10-21
AU2012236603B2 (en) 2015-06-18
RS55014B1 (sr) 2016-11-30
JP2020058363A (ja) 2020-04-16
TW201940510A (zh) 2019-10-16
CN110256569A (zh) 2019-09-20
DK3199547T3 (da) 2021-02-08
MY164906A (en) 2018-02-15
UY33983A (es) 2012-10-31
SI3199547T1 (sl) 2021-03-31
KR102607708B1 (ko) 2023-11-30
EP3199547A1 (en) 2017-08-02
ZA201307017B (en) 2014-05-28
CL2018001827A1 (es) 2018-08-31
RS61399B1 (sr) 2021-02-26
DK2691416T3 (en) 2016-09-05
BR122020011291B1 (pt) 2022-06-14
TW201808994A (zh) 2018-03-16
ES2588306T3 (es) 2016-11-02
US9221917B2 (en) 2015-12-29
TW202212358A (zh) 2022-04-01
TWI838039B (zh) 2024-04-01

Similar Documents

Publication Publication Date Title
AR085726A1 (es) Proteinas de union de tipo anticuerpo con region variable dual que tienen orientacion de la region de union con entrecruzamiento
JP2018087211A5 (es)
Yi et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Sohn et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4
Niu et al. Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis
Xia et al. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines
Frey et al. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium
US10877049B2 (en) Biomarkers for diagnosis and management of neuro-immunological diseases
JP2023065523A (ja) 免疫チェックポイント阻害薬によるがん治療に対する個別化応答の予測方法およびそのためのキット
Middleton et al. Cytokine imbalance in acute rheumatic fever and rheumatic heart disease: Mechanisms and therapeutic implications
Surcel et al. Reinforcing involvement of NK cells in psoriasiform dermatitis animal model
Gonzalez-Orozco et al. Endogenous stimulation is responsible for the high frequency of IL-17A-producing neutrophils in patients with rheumatoid arthritis
Selmi Autoimmunity in 2016
Pavkova Goldbergova et al. Circulating cytokine pattern and factors describing rheumatoid arthritis: IL-15 as one of the biomarkers for RA?
Carrasco et al. Biomarkers of outcome in rheumatoid arthritis
Rodríguez-Carrio et al. Profiling of B-cell factors and their decoy receptors in rheumatoid arthritis: association with clinical features and treatment outcomes
Šenolt et al. Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis
HRP20210240T1 (hr) Vezujući proteini slični protutijelu s dvostrukom varijabilnom regijom koji imaju unakrsno orjentiranu vezujuću regiju
Lu et al. Decreased circulating Th22 and Th17 cells in patients with aplastic anemia
FI3443006T3 (fi) Trispesifisiä ja/tai kolmiarvoisia sitojaproteiineja
Kamperschroer et al. Utilization of lipopolysaccharide challenge in cynomolgus macaques to assess IL-10 receptor antagonism
Manetti et al. FRI0362 angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis
Akiyama et al. FRI0361 Interleukin-4 induces class-switching to IGG4 and synergistically contributes to plasmablasts differentiation with interleukin-21 through CD40 dependent manner in IGG4-related disease
Piccolomini et al. Effects of the incubation in vitro with sorbents on serum proteomic pattern and cytokine concentration in cancer patients during chemotherapy—preliminary results
Hegde et al. Plasma cytokine profiles in preprotachykinin-A knockout mice subjected to polymicrobial sepsis

Legal Events

Date Code Title Description
FC Refusal